ICU: QUELIMMUNE sales surged, while adult-AKI trial enrollment shifted to mid-2027

SeaStar Medical (ICU) reported Q3 2026 revenue growth of 247% YoY, driven by QUELIMMUNE sales. Nine-month sales suggest FY2026 guidance of $2 million is achievable. NEUTRALIZE-AKI trial enrollment delayed to mid-2027, with adult-AKI PMA work ongoing.

Original reporting
Published Nov 11, 2026, 10:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ICU: QUELIMMUNE sales surged, while adult-AKI trial enrollment shifted to mid-2027 — source image
Decision brief

The 30-second read

$ICUBullishMed
01

Why it matters

The earnings beat and achievable guidance provide a fresh catalyst that could attract new buying interest, especially given the high growth rate.

02

Market read

The strong revenue growth and guidance update are likely to lift ICU's stock in the short term, with potential spill‑over to similar biotech peers.

03

What to watch

Potential regulatory hurdles for the adult‑AKI PMA and competition from other renal‑therapy candidates.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

SeaStar Medical Holding Corp (ICU) reported a 247% YoY increase in Q3 revenue and indicated FY2026 guidance of $2 M is within reach, while its NEUTRALIZE‑AKI trial timeline shifts to mid‑2027.

Company-level read

Ticker impact

$ICUBullishHigh confidence
Context

Q3 revenue jumped 247% YoY and FY2026 guidance of $2 M is now within reach, indicating strong sales momentum.

Expected impact

likely upward pressure as investors price in stronger sales and achievable guidance

Evidence & confidence

The disclosed revenue surge and attainable guidance are fresh, material facts that can move the stock.

Market effects

Boosts outlook for biotech firms with late‑stage AKI trials, may lift peer valuations.

Limited to US biotech sector; no broader regional effect.

Minor global impact, confined to specialty renal‑therapy market.

Counterpoint

If trial enrollment delays persist, the guidance may be overly optimistic, risking a pull‑back.

Key entities

  • SeaStar Medical Holding Corp

    US‑listed biotech focused on acute kidney injury therapies.

Related articles

$ICUHigh

SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025 Achieved nearly 75% enrollment in the NEUTRALIZE-AKI p